摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-Chloro-4-(8-piperidinooctylamino)quinoline

中文名称
——
中文别名
——
英文名称
7-Chloro-4-(8-piperidinooctylamino)quinoline
英文别名
7-Chloro4-(8-piperidinooctylamino)quinoline;7-chloro-N-(8-piperidin-1-yloctyl)quinolin-4-amine
7-Chloro-4-(8-piperidinooctylamino)quinoline化学式
CAS
——
化学式
C22H32ClN3
mdl
——
分子量
373.969
InChiKey
HOHHBBVPNOOKBH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.2
  • 重原子数:
    26
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    28.2
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    1,8-二溴辛烷盐酸 、 potassium iodide 、 苯酚 作用下, 以 丙酮 为溶剂, 反应 108.0h, 生成 7-Chloro-4-(8-piperidinooctylamino)quinoline
    参考文献:
    名称:
    与组合抑制组胺N-甲基转移酶活性的新型一类新的非咪唑组胺H(3)受体配体的发展。
    摘要:
    在寻找增强中枢神经系统中组胺能神经传递的新颖方法的同时,开发了一种新型的非咪唑组胺H(3)受体配体,该配体同时对主要组胺代谢酶组胺N-甲基转移酶(HMT)具有较强的抑制活性。新化合物包含氨基喹啉部分,这是HMT抑制活性的重要结构特征,通过不同的间隔基连接到哌啶子基上(对H(3)受体有拮抗作用)。间隔物结构的变化提供了两种不同系列的化合物。一个系列,在基本中心之间只有一个亚烷基间隔基,导致对人组胺H(3)受体具有中等至高亲和力的高效HMT抑制剂。第二系列具有对苯氧丙基间隔基 可以被另一个亚烷基链延长。后一个系列还显示出对HMT的强抑制活性,并且在大多数情况下,H(3)受体的亲和力甚至超过了第一个系列。具有这种双重作用方式的最有效的化合物之一是4-(4-(3-哌啶子基丙氧基)苯氨基)喹啉(34)(hH(3),K(i)= 0.09 nM; HMT,IC(50)= 51 nM)。这类化合物在豚鼠对
    DOI:
    10.1021/jm0110845
点击查看最新优质反应信息

文献信息

  • Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
    申请人:——
    公开号:US20040220225A1
    公开(公告)日:2004-11-04
    Use of a compound of formula (A), wherein: 1 W is a residue which imparts antagonistic and/or agonistic activity at histamine H 3 -receptors when attached to an imidazole ring in 4(5) position; R 1 and R 2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H 3 -receptors of histamine.
    使用式(A)的化合物,其中:1W是一个残基,当附加在咪唑环的4(5)位时,赋予组合物在组胺H3受体上的拮抗和/或激动活性;R1和R2可以相同也可以不同,分别独立地表示较低的烷基或环烷基,或者与它们所连接的氮原子一起,表示饱和的含氮环(i)、非芳香性不饱和含氮环(ii)、吗啡环或N-取代哌嗪环,用于制备在组胺H3受体上作为拮抗剂和/或激动剂的药物。
  • Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications
    申请人:Schwartz Jean-Charles
    公开号:US20060247223A1
    公开(公告)日:2006-11-02
    Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H 3 -receptors when attached to an imidazole ring in 4(5) position; R 1 and R 2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H 3 -receptors of histamine.
    使用公式(A)中的化合物,其中: W是一个残留物,当附加到咪唑环的4(5)位时,赋予组织胺H3受体的拮抗和/或激动活性; R1和R2可以相同也可以不同,并且独立地表示较低的烷基或环烷基,或者与它们附着的氮原子一起,表示饱和的含氮环(i)如定义,非芳香性不饱和含氮环(ii)如定义,吗啉基或N-取代的哌嗪基,如定义,用于制备作为组织胺H3受体的拮抗剂和/或激动剂的药物。
  • NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS
    申请人:SCHWARTZ Jean-Charles
    公开号:US20110281844A1
    公开(公告)日:2011-11-17
    Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H 3 -receptors when attached to an imidazole ring in 4(5) position; R 1 and R 2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H 3 -receptors of histamine.
    使用公式(A)中的化合物,其中: W是一个残基,当连接到咪唑环的4(5)位置时,赋予组合物在组胺H3受体上的拮抗和/或激动活性;R1和R2可能相同也可能不同,且分别独立地代表较低的烷基或环烷基,或者与它们连接的氮原子一起,代表饱和的含氮环(i),如所定义,非芳香性不饱和含氮环(ii),如所定义,吗啡啶基团,或所定义的N-取代哌嗪基团,以制备在组胺H3受体上作为拮抗剂和/或激动剂的药物。
  • Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications
    申请人:BIOPROJET
    公开号:EP1428820A1
    公开(公告)日:2004-06-16
    The present invention provides new non-imidazole alkylamine derivatives, and their use for preparing medicaments acting as antagonists and/or agonists at the H3-receptors of histamine.
    本发明提供了新的非咪唑烷基胺衍生物,以及它们在制备用作组胺 H3 受体拮抗剂和/或激动剂的药物中的用途。
  • Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
    申请人:BIOPROJET
    公开号:EP1707203A1
    公开(公告)日:2006-10-04
    The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H3-receptors of histamine.
    本发明提供了用构成组胺 H3 受体拮抗剂的非咪唑类烷基胺衍生物治疗帕金森病、阻塞性睡眠呼吸暂停、路易体痴呆、血管性痴呆的新方法。
查看更多